Scientific Presentations
Promising data for the ALZ-101 vaccine presented at the AD/PD™ 2023 conference
Dr. Anders Sandberg, Chief Scientific Officer, presented data for the Company’s vaccine candidate ALZ-101. The results from the studies show both long-term efficacy and that antibodies are present in the central nervous system, which is where the effect should be.
Preclinical data on the vaccine candidate show that ALZ-101 has a long-lasting effect and that antibodies can be observed even six months after the last dose. Antibodies increase sharply after refill doses of the vaccine, suggesting that an immunological memory has been created by the immunization. In addition, antibodies can be observed in spinal fluid, suggesting that they reach the central nervous system in expected amounts. The vaccine thus appears to be effective even as a long-term (chronic) treatment. The conclusion is that ALZ-101 stimulates the production of antibodies for a long time, and that these can reach the brain in relevant amounts. The poster also shows base line disease characteristics on all patients included in the ongoing phase 1b clinical trial.
The data were presented at the international conference AD/PD™ 2023 on March 28 – April 1.
Preclinical data presented at, Clinical Trials in Alzheimer’s Disease (CTAD) 2022
Dr. Anders Sandberg, Chief Scientific Officer, presented data for the Company’s preclinical antibody candidate ALZ-201. The poster summarises the development of the monoclonal antibody ALZ-201 and its unique binding profile in relation to other drug candidates in development.
The data show that ALZ-201 differs significantly from lecanemab, aducanumab, and gantenerumab in that, unlike these, binds specifically to a small portion of the amyloid beta known as oligomers. With this targeted binding profile, ALZ-201 has a strong neutralising effect on the toxic form of amyloid beta extracted from the brains of deceased Alzheimer’s patients. Specificity for the amyloid beta that is toxic, is thought to be necessary to obtain a good therapeutic effect in patients with Alzheimer’s disease. The data were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) 2022 on 29 November to 2 December.
Preclinical data presented at Alzheimer’s Association International Conference (AAIC) 2021
Dr. Anders Sandberg, Chief Scientific Officer, presented data on the Company’s monoclonal antibody, ALZ-201. The poster features preclinical data relating to Alzinova’s immunotherapy technology platform that specifically targets the oligomeric, neurotoxic forms of the amyloid-β peptide (Aβ) aggregates, which are considered to be the cause of Alzheimer’s disease.
The preclinical data support the continued development of Alzinova’s lead candidate, ALZ-101, which is further in development. The data were presented at the Alzheimer’s Association International Conference 2021 (AAIC) on 26 July.
Study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 presented at Clinical Trials in Alzheimer’s Disease (CTAD) 2020
Alzinova presented the study design of the upcoming first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 on a poster titled: First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42. The poster was presented at Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, November 4-7, 2020.
Preclinical data presented at Alzheimer’s Association International Conference (AAIC) 2020
Dr. Anders Sandberg, Chief Scientific Officer, presented data on the Company’s substances. The poster provides an overview of the Company’s research strategy and data demonstrating that the monoclonal antibody ALZ-201, which specifically targets Aβ42 oligomers, is able to neutralize the neurotoxic effect as effectively as an antibody that binds to all forms of Aβ. This has been studied in two different preclinical Alzheimer’s disease models based on human brain tissue.
The findings demonstrate that oligomers are present in low levels in the brain of patients, and that targeting these with high specificity is likely required to achieve therapeutic efficacy. The data support the continued development of the Company’s lead candidate, ALZ-101. The data were presented at the Alzheimer’s Association International Conference 2020 (AAIC) on July 29.